Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study

Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yun, Yang, Qing-qing, Zhuo, Lin, Yang, Kun, Kou, Hao, Gao, Su-yu, Hu, Wen, Jiang, Qiao-li, Li, Wen-jing, Wu, Dong-fang, Sun, Feng, Cheng, Hong, Zhan, Siyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582747/
https://www.ncbi.nlm.nih.gov/pubmed/36274736
http://dx.doi.org/10.3389/fmicb.2022.1013038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582747/
https://www.ncbi.nlm.nih.gov/pubmed/36274736
http://dx.doi.org/10.3389/fmicb.2022.1013038

Ejemplares similares